Clinical Utility of Methylation-based Prognostic Assay for Barrett's Esophagus

Status unconfirmed · Not applicable

Conditions studied: Barrett Esophagus, Esophageal Cancer

In brief

Capsulomics has developed a prognostic assay for patients with diagnosed Barrett's esophagus (BE). This study will measure how gastroenterologists make surveillance and treatment management decisions when presented with different clinical and prognostic assay information.

Key facts

Study ID

NCT05846971

Run by

Capsulomics, Inc.

People needed

100

Starts

2021-01-26

Expected to finish

2023-12-31

Last updated by the study team

2023-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be currently practicing board-certified gastroenterologist practicing in the United States
• Have practiced (as a board-certified gastroenterologist) for greater than 2
• Be English-speaking
• Have ≥ 50 Barrett's esophagus patients under care annually
• Have Internet access
• Have no prior experience with the methylation assay test
• Provide voluntary informed consent to participate in the study.

You may not qualify if…

• Non-practicing gastroenterologists
• Less than two years of gastroenterology practice
• Non-English speaking
• Does not have access to the internet
• Does not consent to participate in study

Where it is running

• Capsulomics, Inc. — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.